The document discusses recombinant vaccines and their production. It defines recombinant vaccines as those generated using recombinant DNA technology, with genes encoding antigens isolated from pathogens inserted into nonvirulent viruses or bacteria. There are three main types of recombinant vaccines: recombinant subunit vaccines involving expression of immunogenic proteins, DNA vaccines using genetic material from pathogens, and recombinant vector vaccines inserting pathogen genes into viruses or bacteria. The document outlines the advantages of recombinant vaccines as generating humoral and T-helper immune responses while being safe, inexpensive, and allowing antigens to be made more immunogenic, though they may require multiple doses and adjuvants.

1. PRODUCTION OF
RECOMBINANT
VACCINES
Present by: Sristi Rajput
Roll No.: 201651
M.Sc. Biotechnology
III Semester
Central University of Haryana

2. INTRODUCTION
● Biological preparation that
provides active acquired
immunity
● Stimulates body’s immune
system
● First successful case of
vaccination was performed
by Edward Jenner in 1796

4. APPROACHES FOR VACCINEDEVELOPMENT

5. RECOMBINANT VACCINE
● Generated using recombinant DNA technology
● Manufactured with the assistance of expression systems
Escherichia coli
Ease of
bioprocessing and
scale-up
Strain engineering
Lower cost
Shorter production
time

6. Recombinant
Subunit Vaccines
DNA Vaccines
Use the genetic material
of the pathogen itself to
immunize the individual
Recombinant
Vector Vaccines
Genes that encode
antigens isolated from
a pathogen can be
inserted into
nonvirulent viruses or
bacteria
TYPES OFRECOMBINANTVACCINE
Involves cloning of gene
encoding immunogenic
protein and its
expression in bacterial,
yeast or mammalian
cell

7. RECOMBINANT SUBUNIT VACCINE

8. DNA VACCINES

9. RECOMBINANT VECTOR VACCINE

10. PRODUCTION OF A RECOMBINANT VACCINE
Yeast
Bioreactor
Shaker Incubator
BMMY
YDP
Broth
YPD+Zeocin
Petri Plakasi
Clinical Studies
Purification
Filtration
Preclinical Studies Formulation

11. STAGES FORVACCINE DEVELOPMENT
PRODUCTIONAND
QUALITYCONTROL
APPROVAL
PRECLINICALSTUDIES
CLINICALSTUDIES
1
2
3
4
DISCOVERYSTEPS
5

12. ● Humoral and T-helper cell
response
● Safe
● Antigen can be made more
immunogenic
● Inexpensive
ADVANTAGES

13. ● No cytotoxic T-cell response
● Polysaccharide vaccines can
not be made
● Usually multiple doses
required
● Adjuvants are needed
DISADVANTAGES

14. REFERENCES
https://www.who.int/health-
topics/vaccines-and-
immunization#tab=tab_1
https://www.nature.com/art
icles/d41586-020-01221-y
https://www.youtube.com/w
atch?v=BujoT1ZejZM
https://www.ncbi.nlm.nih.go
v/pmc/articles/PMC385421
2/
https://www.genscript.com/
recombinant-vaccine.html
https://www.youtube.com/w
atch?v=9KmqRu6rs78

15. THANKS!